| Cardiovascular Diseases
Crestor vs Victoza
Side-by-side clinical, coverage, and cost comparison for cardiovascular diseases.Deep comparison between: Crestor vs Victoza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVictoza has a higher rate of injection site reactions vs Crestor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Victoza but not Crestor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Crestor
Victoza
At A Glance
Oral
Once daily
HMG-CoA reductase inhibitor
SC injection
Daily
GLP-1 receptor agonist
Indications
- Cardiovascular Diseases
- Hyperlipidemia
- Atherosclerosis
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
Dosing
Cardiovascular Diseases, Hyperlipidemia, Atherosclerosis, Hypertriglyceridemia 5-40 mg orally once daily in adults.
Hypercholesterolemia, Familial HeFH: 5-10 mg once daily (ages 8 to <10 years) or 5-20 mg once daily (ages 10+); HoFH: 20 mg once daily (ages 7+); adults: 5-40 mg once daily.
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases (Adults) Start at 0.6 mg SC once daily for one week, then increase to 1.2 mg once daily; if additional glycemic control is required, increase to 1.8 mg once daily (maximum) after at least one week at 1.2 mg.
Diabetes Mellitus, Non-Insulin-Dependent (Pediatric >= 10 years) Start at 0.6 mg SC once daily; increase in 0.6 mg increments after at least one week on the current dose; maximum recommended dose is 1.8 mg once daily.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to rosuvastatin or any excipient in CRESTOR
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity reaction to liraglutide or any excipient in VICTOZA
Adverse Reactions
Most common (>=2%) headache, nausea, myalgia, asthenia, constipation, arthralgia, dizziness, increased CPK, abdominal pain, diabetes mellitus
Serious myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, proteinuria, hematuria, increases in HbA1c and fasting serum glucose
Postmarketing thrombocytopenia, hepatitis, jaundice, hepatic failure, peripheral neuropathy, cognitive impairment, myasthenia gravis, depression, sleep disorders, gynecomastia, interstitial lung disease, DRESS, lichenoid drug eruption
Most common (>=5%) Nausea, diarrhea, headache, nasopharyngitis, vomiting, decreased appetite, dyspepsia, upper respiratory tract infection, constipation, back pain
Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, dehydration, elevations of liver enzymes, hyperbilirubinemia, cholestasis, cholecystitis, cholelithiasis, hepatitis, angioedema, anaphylactic reactions, pruritus, medullary thyroid carcinoma, dysgeusia, dizziness, dysesthesia, pulmonary aspiration, acute renal failure, increased serum creatinine, cutaneous amyloidosis, alopecia
Pharmacology
CRESTOR (rosuvastatin) is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate (a cholesterol precursor); inhibition accelerates hepatic LDL-receptor expression, reducing plasma LDL-C, total cholesterol, and VLDL levels.
GLP-1 receptor agonist; liraglutide is an acylated human GLP-1 analog (97% amino acid sequence homology to endogenous human GLP-1(7-37)) that stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, and delays gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Crestor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
Victoza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Crestor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Victoza
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Crestor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Victoza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Crestor.
No savings programs available for Victoza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CrestorView full Crestor profile
VictozaView full Victoza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.